martes, 3 de diciembre de 2019

Did someone say CBD drugs?

D.C. Diagnosis
Nicholas Florko

Did someone say CBD drugs?

Greenwich Biosciences, the company behind the only FDA-approved CBD-based drug, Epidiolex, will hold a congressional staff briefing Thursday on potential pharmaceutical uses of CBD ... and it’s clear the maker of your corner-store CBD isn’t getting an invite. 

The invite reads more like an investigation into the abuses of the CBD industry than a briefing on the companies investing in CBD science. “CBD manufacturers promote and market their products for a wide variety of medical uses not endorsed by FDA,” the invite states. “Unlawfully marketed products undermine the rigorous process required for FDA approval.”

It’s not all that surprising, since Greenwich has long complained that unscrupulous behavior from CBD supplement makers could sour the future for companies like theirs that invest millions in developing FDA-approved CBD drugs. But it’s setting up an interesting conflict, that’s for sure. The briefing comes as supplement trade groups are pushing Congress to severely curtain the FDA’s ability to regulate CBD supplements — the opposite of what Greenwich is pushing.

By the way, if you’re thinking, “Why all this drama? Are companies even developing CBD drugs? I’ve got you covered

No hay comentarios: